PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30385727-0	2018	Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.	Oligonucleotides	10-25	ataxin 1	Mus musculus	35-43	
32818920-0	2020	Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment.	Oligonucleotides	10-25	ataxin 1	Mus musculus	66-74	
32818920-4	2020	Here, we tested whether an antisense oligonucleotide (ASO)-mediated reduction of Atxn1 produced unwanted effects involving BACE1, CIC activity, or reduction in hippocampal neuronal precursor cells.	Oligonucleotides	37-52	ataxin 1	Mus musculus	81-86	
31394429-0	2019	Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide.	Oligonucleotides	102-117	ataxin 1	Mus musculus	53-57	
30385727-0	2018	Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.	Oligonucleotides	10-25	ataxin 1	Mus musculus	75-79	
30385727-4	2018	Here, we investigated the therapeutic capability of an antisense oligonucleotide (ASO) targeting mouse Atxn1 in Atxn1154Q/2Q-knockin mice that manifest motor deficits and premature lethality.	Oligonucleotides	65-80	ataxin 1	Mus musculus	103-108